SANOFI HAS FOUR POTENTIAL CANDIDATES FOR STERLING IN U.S., INCLUDING THREE IN LATE-STAGE CLINICALS; JOINT VENTURE WILL HAVE $ 500 MIL. R&D BUDGET, $ 2.3 BIL. SALES